http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Nov 2025 17:30:53 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html <p>Artisan Therapeutics and Tulex Pharmaceuticals announced results from a phase 2a clinical trial of ART-501, an oral liquid extended-release formulation being developed for autism spectrum disorder treatment.</p> <p>The pilot study enrolled six adult participants with confirmed autism spectrum disorder at two U.S. clinical sites. Four of the six participants showed clinical benefit signs, according to the companies. Five participants completed the treatment protocol.</p> <p>The trial measured behavioral improvements using the Aberrant Behavior Checklist – Second Edition (ABC-2). Participants showed reductions in ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 treatment compared to baseline measurements.</p> <p>The study design included http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html Mon, 17 Nov 2025 17:30:53 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html <p>Artisan Therapeutics and Tulex Pharmaceuticals announced results from a phase 2a clinical trial of ART-501, an oral liquid extended-release formulation being developed for autism spectrum disorder treatment.</p> <p>The pilot study enrolled six adult participants with confirmed autism spectrum disorder at two U.S. clinical sites. Four of the six participants showed clinical benefit signs, according to the companies. Five participants completed the treatment protocol.</p> <p>The trial measured behavioral improvements using the Aberrant Behavior Checklist – Second Edition (ABC-2). Participants showed reductions in ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 treatment compared to baseline measurements.</p> <p>The study design included http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html Mon, 17 Nov 2025 17:30:53 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html <p>Artisan Therapeutics and Tulex Pharmaceuticals announced results from a phase 2a clinical trial of ART-501, an oral liquid extended-release formulation being developed for autism spectrum disorder treatment.</p> <p>The pilot study enrolled six adult participants with confirmed autism spectrum disorder at two U.S. clinical sites. Four of the six participants showed clinical benefit signs, according to the companies. Five participants completed the treatment protocol.</p> <p>The trial measured behavioral improvements using the Aberrant Behavior Checklist – Second Edition (ABC-2). Participants showed reductions in ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 treatment compared to baseline measurements.</p> <p>The study design included http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html Mon, 17 Nov 2025 17:30:53 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html <p>Artisan Therapeutics and Tulex Pharmaceuticals announced results from a phase 2a clinical trial of ART-501, an oral liquid extended-release formulation being developed for autism spectrum disorder treatment.</p> <p>The pilot study enrolled six adult participants with confirmed autism spectrum disorder at two U.S. clinical sites. Four of the six participants showed clinical benefit signs, according to the companies. Five participants completed the treatment protocol.</p> <p>The trial measured behavioral improvements using the Aberrant Behavior Checklist – Second Edition (ABC-2). Participants showed reductions in ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 treatment compared to baseline measurements.</p> <p>The study design included http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html Mon, 17 Nov 2025 17:30:53 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html <p>Artisan Therapeutics and Tulex Pharmaceuticals announced results from a phase 2a clinical trial of ART-501, an oral liquid extended-release formulation being developed for autism spectrum disorder treatment.</p> <p>The pilot study enrolled six adult participants with confirmed autism spectrum disorder at two U.S. clinical sites. Four of the six participants showed clinical benefit signs, according to the companies. Five participants completed the treatment protocol.</p> <p>The trial measured behavioral improvements using the Aberrant Behavior Checklist – Second Edition (ABC-2). Participants showed reductions in ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 treatment compared to baseline measurements.</p> <p>The study design included http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html Mon, 17 Nov 2025 17:30:53 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html <p>Artisan Therapeutics and Tulex Pharmaceuticals announced results from a phase 2a clinical trial of ART-501, an oral liquid extended-release formulation being developed for autism spectrum disorder treatment.</p> <p>The pilot study enrolled six adult participants with confirmed autism spectrum disorder at two U.S. clinical sites. Four of the six participants showed clinical benefit signs, according to the companies. Five participants completed the treatment protocol.</p> <p>The trial measured behavioral improvements using the Aberrant Behavior Checklist – Second Edition (ABC-2). Participants showed reductions in ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 treatment compared to baseline measurements.</p> <p>The study design included http://www.streetinsider.com/FDA/Artisan+Therapeutics+reports+phase+2a+trial+results+for+autism+drug/25626405.html Mon, 17 Nov 2025 17:30:53 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Press+Releases/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987 http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html <p align="left">SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.</p> <p align="left">Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable http://www.streetinsider.com/Globe+Newswire/Artisan+Therapeutics+and+Tulex+Pharmaceuticals+Announce+Positive+Phase+2a+Results+for+ART-501%2C+a+Novel+Oral+Liquid+Extended-Release+Formulation+for+Autism+Spectrum+Disorder/25626403.html Mon, 17 Nov 2025 17:30:00 -0500 1799 A.50200218 A.50205019 O.00706867 O.01230641 O.47050987